Powin Biomedical Co., Ltd.
Update：2026/01/07
Industries
Main Industry
Biotechnology
Main Product/Service
Challenges
Economic Losses:
The COVID-19 pandemic has caused significant economic losses exceeding 20 trillion USD globally.
Vaccine Hesitancy:
Despite the introduction of mRNA vaccines, vaccine hesitancy among the public continues to persist.
Evolvin
Economic Losses:
The COVID-19 pandemic has caused significant economic losses exceeding 20 trillion USD globally.
Vaccine Hesitancy:
Despite the introduction of mRNA vaccines, vaccine hesitancy among the public continues to persist.
Evolvin
Founded Year
2021
Unified Business No.
91044533
Status
Active
Number of Employees
0
Total Paid-in
Capital
40,500,000 (NT$)
Location of Company
Taiwan
, Taichung City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Intelligene stands as one of the pioneering drug development companies in Taiwan's biotechnology sector. We are at the forefront of advancing gene therapeutics through siRNA-based drugs, utilizing a revolutionary approach that harnesses the power of RNA i
